• EZ Cap™ Firefly Luciferase mRNA: Translational Signal

  2026-09-08

  A thought-leadership framework for using Cap1 firefly luciferase mRNA as a systems-level reporter of delivery, translation, stability, and gene regulation—while translating new insights on N4-acetylcytidine into disciplined experimental design.

• Native PAGE for Translational CF Research

  2026-09-08

  A translational framework for combining iPSC-derived airway function with native protein analysis. The article explains how native protein gel electrophoresis can preserve biochemical context, clarify genotype-to-phenotype mechanisms, and strengthen decision-making around CFTR variant research.

• TRIM21, ERK1/2, and Drug Resistance in Pituitary Adenomas

  2026-09-07

  The reference study identifies TRIM21 as a context-dependent regulator of ERK1/2 signaling, pituitary adenoma proliferation, and resistance to dopamine agonists. Its combination of CRISPR screening, biochemical validation, and drug screening positions TRIM21 as a preclinical therapeutic target and identifies Quisinostat as a candidate for reducing TRIM21-associated tumor phenotypes.

• Bacitracin B1670: Practical Research Workflow

  2026-09-07

  Bacitracin B1670 is a peptide antibiotic for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis disruption. This guide covers solvent selection, assay controls, storage, and troubleshooting while excluding diagnostic, clinical, and medical use.

• EdU Flow Cytometry Assay Kits (Cy3)

  2026-09-05

  A practical, scenario-driven guide to using EdU Flow Cytometry Assay Kits (Cy3), SKU K1077, for DNA replication measurement, cell-cycle profiling, and cytotoxicity research. It explains assay selection, CuAAC workflow control, multiplex compatibility, interpretation limits, and vendor reliability using evidence-based laboratory practices.

• Therapy Sequencing in Waldenström Macroglobulinemia

  2026-09-04

  The reference article presents a genotype- and patient-centered framework for sequencing therapies in Waldenström macroglobulinemia rather than endorsing a single universal regimen. Its central contribution is linking MYD88 and CXCR4 status with treatment selection while integrating symptoms, comorbidities, toxicity, patient preferences, relapse context, and clinical-trial access.

• Vemurafenib: Mapping BRAF Resistance in Melanoma

  2026-09-04

  Vemurafenib (PLX4032, RG7204) is more than a BRAF V600E inhibitor: it is a controllable perturbation tool for connecting MAPK pathway dependence with adaptive resistance, ARID1A-linked rewiring, and translational melanoma biology.

• Perifosine (KRX-0401) Workflow for Akt and Apoptosis

  2026-09-03

  Perifosine (KRX-0401) enables mechanism-focused studies of Akt inhibition, caspase-dependent apoptosis, and radiation sensitization in cancer cells. This workflow also shows how to use it cautiously as a pathway perturbation in oxygen-glucose deprivation/reoxygenation models inspired by a cerebral ischemia study.

• H2S Deficiency and ER Stress in Diabetic Cardiomyopathy

  2026-09-03

  Guo et al. identify reduced endogenous hydrogen sulfide production as a mechanistic contributor to lipotoxic myocardial injury in diabetic cardiomyopathy, with endoplasmic reticulum stress positioned as a key downstream pathway. By integrating patient samples, diabetic rats, and palmitate-treated cardiomyocytes, the study shows that H2S replacement and ER-stress inhibition produce concordant protective effects.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-09-02

  Masitinib (AB1010) provides a DMSO-compatible way to investigate KIT- and PDGFR-dependent signaling, including models relevant to GIST, mastocytosis, and inflammatory biology. It should be reserved for validated research workflows requiring targeted kinase perturbation and avoided in assays dependent on water or ethanol solubility or broad-spectrum kinase inhibition.

• CKI 7 Dihydrochloride: CK1 Assay Workflows

  2026-09-02

  Build cleaner kinase, signaling, circadian, and cancer-cell experiments with CKI 7 dihydrochloride, while separating pathway-specific effects from general cytotoxicity. The workflow also shows how CK1 perturbation can complement, but not replace, mechanistic testing of the MAPK10–KRT16–RNF213 axis in NSCLC models.

• L-NAME Hydrochloride: NOS Inhibition Guide

  2026-09-01

  L-NAME Hydrochloride, also called NG-nitro-L-arginine methyl ester, is a competitive nitric oxide synthase inhibitor used to reduce nitric oxide synthesis in vascular, cellular, and cardiovascular disease model research. Its documented effects include dose-dependent vascular responses in rats and context-dependent suppression of NO, prostaglandin E2, iNOS, and COX-2 in high-glucose retinal cells.

• CFTRinh-172: Functional Assays After Trafficking

  2026-09-01

  CFTRinh-172 is a selective CFTR inhibitor that helps determine whether changes in channel surface abundance produce real transport effects. This article presents a mechanistic assay framework connecting CFTR trafficking, epithelial chloride secretion, and disease-relevant interpretation.

• P2RX1, CaMKII, and Mitochondrial Apoptosis in Ph+ ALL

  2026-08-31

  Li et al. identify P2RX1 as a regulator of tyrosine kinase inhibitor–associated mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia. Their data connect calcium dysregulation and CaMKII hyperactivation with suppression of PI3K/Akt survival signaling, providing a mechanistic framework for studying treatment response and resistance in Ph+ ALL.

• Estradiol and CD4+ T-Cell Recovery After Hemorrhagic Shock

  2026-08-31

  The reference study identifies endoplasmic reticulum stress as a mechanistic link between hemorrhagic shock and impaired splenic CD4+ T-lymphocyte function. Its pharmacological experiments indicate that estradiol acts predominantly through ERα and GPR30, rather than ERβ, to reduce stress-associated immune dysfunction.

7934 records 1/529 page Next 12345 下5页 Last page